Results 161 to 170 of about 47,525 (299)
Разработка и регистрация лекарственных средств, 2019 Simultaneous quantification method of assaying main CYP isoforms substrates-markers and their metabolites in urine using HPLC-MS/MS was developed to determine activity of following isoforms: caffeine/paraxanthine for CYP1A2, losartane/E-3174 for CYP2C9 ...
E. A. Egorenkov, V. V. Smirnov
doaj
Polymorphic drug metabolising enzymes:Assessment of activities by phenotyping and genotyping in clinical pharmacology [PDF]
, 2001 Drug effects (pharmacodynamics) are determined by drug concentration at target site and the affinity of the drug for a target. Pharmacogenetics describes inherited differences in drug metabolising enzyme activities and differences in drug transporters ...
Tamminga, Willem Jan
core +2 more sources
The role of CYP2D6 in the metabolism of antidepressants
GSC Biological and Pharmaceutical SciencesThe cytochrome P450 2D6 plays an important role in the metabolism of several drugs, including antidepressants, and it also influences their efficacy and adverse effects. Some of the CYP2D6 genetic variants are closely related with a different metabolism way, depending on its type (PM, MI, normal, UM); that impacts mostly reducing the pharmacologic ...
Ximena-Chávez +4 more
openaire +1 more source
Clinical Pharmacology &Therapeutics, Volume 118, Issue 4, Page 885-893, October 2025.The US Food and Drug Administration 2024 guidance prefers regression analysis over categorical analysis for pharmacokinetic data for studies that assess pharmacokinetics in patients with impaired renal functions. The objective of this study was to compare these two statistical methods for pharmacokinetic data analysis of renal impairment studies ...
Gerald Chun‐To So +7 more
wiley +1 more source
P02.321 Occurrence of CYP2D6 gene duplication in Hong Kong Chinese [PDF]
, 2000 Lok Yee Chow +5 more
openalex +1 more source
Clinical Pharmacology &Therapeutics, Volume 118, Issue 4, Page 906-916, October 2025.Germline pharmacogenetics (PGx) is increasingly used to tailor medication selection/dosing. However, existing systems primarily communicate PGx results to providers, limiting direct patient engagement. To address this, we developed YourPGx Oncology, an innovative patient‐facing portal that delivers multi‐gene PGx results (CYP2D6, UGT1A1, DPYD) through ...
Youngwoo Cho +15 more
wiley +1 more source
Frontiers in PharmacologyBackground: Tramadol is primarily metabolized by the highly polymorphic CYP2D6 enzyme, leading to a large spectrum of adverse events and clinical response.
Mahmood Mahajna +11 more
doaj +1 more source
Pharmacogenetic Implementation Studies—Lessons Learned From the PREPARE Study
Clinical Pharmacology &Therapeutics, Volume 118, Issue 4, Page 803-812, October 2025.The Ubiquitous Pharmacogenomics consortium (www.upgx.eu) has recently completed and published the Preemptive Pharmacogenomic Testing for Preventing Adverse Drug Reactions (PREPARE) study on the implementation of panel‐based pharmacogenetic testing. PREPARE has provided interesting lessons for the design, execution, and interpretation of future clinical
Henk‐Jan Guchelaar +37 more
wiley +1 more source
Prospective assessment of CYP2D6 by genotyping, phenotyping and measurement of tamoxifen, PD 05-09 4-hydroxy-tamoxifen and endoxifen in breast cancer patients treated with tamoxifen. [PDF]
, 2010 Tamoxifen (tam) is a widely used endocrine therapy in the treatment of early and advanced stage breast cancer in women and men. It is a pro-drug having weak affinity with the estrogen receptor and needs to be converted to its main metabolite, endoxifen ...
Berthod, G. +10 more
core
Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes [PDF]
, 2001 Chiaki Senda +7 more
openalex +1 more source